نتایج جستجو برای: oncogene proteins c

تعداد نتایج: 1518083  

2014
ANDRES SILVA JENNIE WANG SARAH LOMAHAN TUAN-ANH TRAN LAURA GRENLIN AKIKO SUGANAMI YUTAKA TAMURA NAOHIKO IKEGAKI

OSU-03012, a 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitor, destabilizes MYCN and MYC proteins in neuroblastoma cells. However, AKT phosphorylation is barely detectable in neuroblastoma cells under normal culture conditions whether treated with OSU-03012 or not. This observation suggests that PDK1 is not the main target of OSU-03012 to destabilize MYC and MYCN in neuroblastoma cells. I...

Journal: :Cancer research 2013
Carla Boccaccio Paolo M Comoglio

The MET oncogene, a crucial regulator of the genetic program known as "invasive growth" or "epithelial-mesenchymal transition," has recently emerged as a functional marker of glioblastoma stem cells. Here, we review findings that associate MET expression and activity with a specific, genetically defined glioblastoma stem cell subtype, and data showing how MET sustains the stem cell phenotype in...

Journal: :hepatitis monthly 0
mohammad reza hajizadeh recombinant proteins lab, biochemistry department, medical school, shiraz university of medical sciences, shiraz, ir iran pooneh mokarram recombinant proteins lab, biochemistry department, medical school, shiraz university of medical sciences, shiraz, ir iran; gastroentrohepatology research center, medical school, shiraz university of medical sciences, shiraz, ir iran eskandar kamali sarvestani immunology department, medical school, shiraz university of medical sciences, shiraz, ir iran azam bolhassani molecular immunology and vaccine research laboratory, pasteur institute of iran, tehran, ir iran zohreh mostafavi pour recombinant proteins lab, biochemistry department, medical school, shiraz university of medical sciences, shiraz, ir iran; faculty for advanced biomedical sciences, shiraz university of medical sciences, shiraz, ir iran; recombinant proteins lab, biochemistry department, faculty for advanced biomedical sciences, shiraz university of medical sciences, p.o. box: 71345-1167. shiraz, ir iran. tel: +98-7112303029, fax: +98-7112303029

conclusions we have highlighted the role of rns3 plus rnt-gp96 mediated by α5integrin in producing il-12 and tnfα. it can be suggested that rnt-gp96 could enhance immunity characteristic of rns3 protein via production of pro-inflammatory cytokines. results our results showed that rnt-gp96 alone significantly increases the expression level of il-12, tnfα and α5integrin in thp-1 macrophages and d...

Journal: :Revista Brasileira de Cancerologia 2006

Journal: :Atlas of Genetics and Cytogenetics in Oncology and Haematology 2010

Journal: :Atlas of Genetics and Cytogenetics in Oncology and Haematology 2011

Journal: :Cancer research 2013
Anchit Khanna John E Pimanda Jukka Westermarck

Protein phosphatase 2A (PP2A) complexes function as tumor suppressors by inhibiting the activity of several critical oncogenic signaling pathways. Consequently, inhibition of the PP2A phosphatase activity is one of many prerequisites for the transformation of normal human cells into cancerous cells. However, mechanisms for PP2A inactivation in human cancers are poorly understood. The aberrant e...

Journal: :The Journal of biological chemistry 2002
Zhao Mei Mu Xiao Ying Yin Edward V Prochownik

The highly conserved Myc Box II (MBII) domain of c-Myc is critically important for transformation and transcriptional regulation. A yeast two-hybrid screen identified Pag as a MBII-interacting protein. Pag, a member of the peroxiredoxin family, has been reported previously to bind to and inhibit the cytostatic properties of the c-Abl oncoprotein. We now show that Pag promotes increased cell siz...

Journal: :Cancer research 2014
Carmen Priolo Saumyadipta Pyne Joshua Rose Erzsébet Ravasz Regan Giorgia Zadra Cornelia Photopoulos Stefano Cacciatore Denise Schultz Natalia Scaglia Jonathan McDunn Angelo M De Marzo Massimo Loda

Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید